Keynote by co-founder Professor Jean-Louis Reymond highlights next-generation approaches to exploring peptide chemical space for first-in-class therapeutics
Beijing, China – July 2026 – Space Peptides today announced its participation in the 19th China International Peptide Symposium (CPS 2026), one of the world’s leading scientific conferences dedicated to peptide science and therapeutics. During the conference, held in Beijing from July 5–7, Professor Jean-Louis Reymond, internationally recognized pioneer of chemical space research, Dean of the Faculty of Science at the University of Bern, and co-founder of Space Peptides, delivered a keynote lecture on the latest advances in machine learning-guided exploration of peptide chemical space.
Professor Reymond’s presentation, “Machine Learning Guided Discoveries in the Unknown Peptide Chemical Space,” highlighted emerging computational approaches that enable researchers to identify novel peptide drug candidates far beyond the limits of conventional discovery methods. His work has fundamentally shaped the field through the creation of the Generated Database (GDB), the PepSpace™ virtual peptide chemical space, and advanced computational methodologies for peptide design and virtual screening.
Building on these scientific foundations, Space Peptides has translated Professor Reymond’s pioneering research into an industrial AI-powered drug discovery platform that combines the ultra-large PepSpace™ database with proprietary machine learning algorithms, peptide design technologies, and multidimensional chemical space analytics. The platform enables the rapid identification and optimization of differentiated peptide leads—including cyclic peptides, dendritic peptides, and D-amino acid-containing structures—while accelerating the discovery of first- and best-in-class therapeutic candidates with reduced intellectual property risk.
By integrating computational peptide discovery with process development, peptide synthesis, and GMP manufacturing, Space Peptides offers pharmaceutical and biotechnology companies a seamless pathway from target identification through clinical development and commercial manufacturing. This fully integrated approach significantly shortens development timelines while increasing the probability of identifying innovative peptide therapeutics.
During CPS 2026, the Space Peptides team engaged with leading academic researchers, biotechnology innovators, and pharmaceutical companies to discuss how artificial intelligence and chemical space technologies are reshaping peptide drug discovery. The conference provided an important platform to strengthen scientific collaborations and further establish Space Peptides as a global innovation partner in peptide therapeutics.
“The future of peptide therapeutics will be defined by our ability to intelligently navigate an almost infinite chemical universe,” said Dr. Runze He, Chief Executive Officer of Space Peptides. “Our collaboration with Professor Jean-Louis Reymond and the translation of his groundbreaking scientific discoveries into an industrial AI platform uniquely positions Space Peptides to help pharmaceutical innovators identify differentiated peptide drug candidates faster, with greater confidence and a significantly higher probability of success. Presenting these capabilities at CPS 2026 reinforces our commitment to advancing the next generation of peptide medicines through scientific excellence, artificial intelligence and integrated development capabilities.”
As demand for innovative peptide therapeutics continues to accelerate globally, Space Peptides remains committed to expanding the frontiers of peptide drug discovery by combining world-class computational science, artificial intelligence, and integrated CRDMO capabilities to support customers from discovery through commercial manufacturing.
About Space Peptides
Headquartered in Switzerland with global operations, Space Peptides provides end-to-end pharmaceutical Peptide CRDMO services—covering discovery, process development, and GMP manufacturing. With a strong commitment to innovation, quality, and sustainability, Space Peptides is shaping the future of peptide therapeutics manufacturing.